Brind.

Lara Campana is SVP at Resolution Therapeutics, which is conducting a Phase 1/2 study named EMERALD.

1 report, 1 independent Updated Jun 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Lara Campana is SVP at Resolution Therapeutics, which is conducting a Phase 1/2 study named EMERALD.

Who's involved

What this event is mainly about
Lara CampanaEmerald

Keep exploring

The entities involved

  • Emerald

    programming language

    Nothing else this week.

Coverage

Newest first; wire copies grouped